Flowchart on how we use genomic assays for diagnosis (A) and for prognostication in patients (B) with an established diagnosis of MPN. Selected information (cytogenetics, JAK2 V617F and CALR mutations) collected at the time of diagnosis may also inform risk scores at step B. NGS analysis for myeloid genes, if not available at the time of original investigation, is recommended in patients with PMF and sMF who are transplant eligible. PET, post-ET; PPV, post-PV.